[(19S)-8-[(dimethylamino)methyl]-19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] N-[7-(hydroxyamino)-7-oxoheptyl]carbamate | 1386978-12-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: [(19S)-8-[(dimethylamino)methyl]-19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] N-[7-(hydroxyamino)-7-oxoheptyl]carbamate
• CAS: 1386978-12-6
• 化学式: C₃₁H₃₇N₅O₈
• 分子量: 607.663
• InChiKey: GXJCTHBQDINYBL-HKBQPEDESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  44
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  171
• 氢给体数：
  4
• 氢受体数：
  10

文献信息

• HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN
  申请人：Chen Yi

  公开号：US20130281402A1

  公开（公告）日：2013-10-24

  The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R 1 , R 2 , and R 3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.

  本公开涉及式I的羟肟酰胺化合物：（式I），其中Z，L，R1，R2和R3的定义如本文所述。还公开了使用这些化合物治疗肿瘤性疾病或免疫性疾病的方法。
• US8980909B2
  申请人：——

  公开号：US8980909B2

  公开（公告）日：2015-03-17
• [EN] HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN<br/>[FR] DÉRIVÉS DE CAMPTOTHÉCINE INHIBITEURS DE HDAC
  申请人：CRYSTAL BIOPHARMACEUTICAL LLC

  公开号：WO2012096832A2

  公开（公告）日：2012-07-19

  The disclosure includes hydroxamic compounds of Formula I: (Formula I) wherein Z, L, R1, R2, and R3 are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.